Search results
Showing 721 to 735 of 2008 results for nice guidelines
Antimicrobial prescribing: imipenem with cilastatin and relebactam (ES30)
Summary of the evidence on antimicrobial prescribing: imipenem with cilastatin and relebactam
Evidence-based recommendations on clopidogrel and modified-release dipyridamole for preventing occlusive vascular events in adults.
The NICE public health guidance development process (third edition) (PMG5)
This manual describes how public health guidance is produced, and explains the stages of guidance development, the different activities, roles and responsibilities of different groups of people involved at different stages
This indicator covers the percentage of mothers who give their babies breast milk in the first 48 hours after delivery. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG33
This indicator covers the the percentage of patients with a current diagnosis of heart failure with reduced ejection fraction, who are currently treated with an angiotensin-converting enzyme inhibitor or angiotensin receptor-neprilysin inhibitor or angiotensin II receptor blocker, a beta blocker, a mineralocorticoid receptor antagonist and a sodium glucose co-transporter-2 inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This guideline covers planning and delivering multi-agency services for domestic violence and abuse. It aims to help identify, prevent and reduce domestic violence and abuse among women and men in heterosexual or same-sex relationships, and among young people.
Secukinumab for treating moderate to severe plaque psoriasis (TA350)
Evidence-based recommendations on secukinumab (Cosentyx) for treating plaque psoriasis in adults.
This indicator covers patient experiences of GP services. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Diabetes: lipid-lowering therapies for secondary prevention of CVD (IND276)
This indicator covers the percentage of patients with diabetes and a history of cardiovascular disease (excluding a history of haemorrhagic stroke) who are currently treated with a lipid-lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers patient experiences of A&E. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers patient experiences of hospital. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)
Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making
Hip fracture: surgery on the day or day after admission (IND14)
This indicator covers the proportion of people with hip fracture, who receive surgery on the day of, or the day after, admission. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG21
Our Medical Technologies Evaluation Programme (MTEP) evaluates new HealthTech.
We work with the clinical classifications service of NHS Digital to provide relevant clinical coding information for interventional procedure and medical technologies guidance.